tradingkey.logo

BRIEF-Immix Biopharma Receives FDA RMAT Designation For NXC-201

ReutersFeb 10, 2025 3:15 PM

- Immix Biopharma Inc IMMX.O:

  • IMMIX BIOPHARMA RECEIVES FDA REGENERATIVE MEDICINE ADVANCED THERAPY (RMAT) DESIGNATION FOR NXC-201, STERICALLY-OPTIMIZED CAR-T FOR RELAPSED/REFRACTORY AL AMYLOIDOSIS

  • IMMIX BIOPHARMA INC: ENROLLMENT IN NEXICART-2 STUDY ACCELERATING; NEXT UPDATE PLANNED FOR H1 2025

Source text: ID:nGNXbjs757

Further company coverage: IMMX.O

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI